Cardinal Health (CAH), a services company in healthcare industry, has a series of interesting developments. Intrinsic valuation details suggest the firm is 33% undervalued. CAH reaffirmed its long-term growth while raising its outlook. Despite some dips, CAH is consistently perceived as a high-ranking momentum stock with potential multi-bagger qualities. Q1 performance missed revenue estimates, yet profit expectations in the face of tariff headwinds were exceeded. Guidance for FY2025 was also raised due to strong pharma growth and acquisitions. CAH displayed strong equity momentum and released a new report on the cell and gene therapy industry. An innovative single-patient monitoring system was also launched which monitors three vital signs in one system. Analysts’ opinions remain mixed - Cowen remains bullish while Wall Street's forecasts are varied. Institutional ownership of CAH is high, reaching 89% at one point. News about strategic portfolio additions, increased divident and a strong second quarter performance contributed to its strong momentum. Risks and potential tariff costs are present, yet CAH managed to beat EPS expectations while its stock soars to all-time highs. Notably, the company also entered into major distribution deals and increased its investor day outlook on earnings.
Cardinal Health CAH News Analytics from Fri, 01 Nov 2024 07:00:00 GMT to Fri, 20 Jun 2025 22:15:02 GMT -
Rating 8
- Innovation 9
- Information 7
- Rumor 6
